This author has not written his bio yet.
But we are proud to say that PR Newswire contributed 415 entries already.
Kintara Therapeutics Inc. and TuHURA Biosciences Inc. announced that they have entered into a definitive agreement for an all-stock transaction forming a company with expertise and resources to advance a risk-diversified late-stage oncology pipeline.
The U.S. Food and Drug Administration (FDA) has approved Abbott’s first-of-its-kind TriClip transcatheter edge-to-edge repair (TEER) system that’s specifically designed for the treatment of tricuspid regurgitation (TR), or a leaky tricuspid valve.
Canada’s largest pharmaceutical company, Apotex Incand Searchlight Pharma Inc., one of Canada’s fastest growing companies, announced that they have reached an agreement whereby Apotex will acquire Searchlight.
Abbott’s i-STAT TBI cartridge has received clearance from the U.S. Food and Drug Administration (FDA) to be used with whole blood, allowing doctors to help assess patients with suspected concussion at the patient’s bedside and obtain lab-quality results in 15 minutes. Previously, the tests to help with the assessment of TBI were only cleared for use with plasma or serum, requiring samples to be sent to a lab for processing and testing.
If shown to be well-tolerated and effective, M72/AS01E could potentially become the first vaccine to help prevent pulmonary TB in adolescents and adults, the most common form of the disease, and the first new TB vaccine in over a century. The first doses were given in South Africa, where TB takes a heavy toll.
Eli Lilly announced late-breaking results from a first-of-its-kind study of lebrikizumab specifically designed for people with skin of color and moderate-to-severe atopic dermatitis, commonly called eczema. In this study, treatment with lebrikizumab, an investigational medicine, showed improvement in skin clearance and itch relief.
Abbott, the global leader in screening blood and plasma, partnered with Blood Centers of America, the largest blood supplier network in the U.S., to launch a mixed reality experience for blood donors in June 2023. Results from a pilot study reveal that mixed reality “is an innovative technology that holds promise to increase donor engagement, satisfaction, and retention,” researchers said.
Elpiscience Biopharma, Ltd. announced a research collaboration and license agreement for novel bi-specific macrophage engagers, ES019, and another program.
Mallinckrodt plc, a global specialty pharmaceutical company, today announced that it received a score of 100 on the Human Rights Campaign Foundation’s 2023-2024 Corporate Equality Index, the nation’s foremost benchmarking survey and report measuring corporate policies and practices related to LGBTQ+ workplace equality.
Amgen announced that the U.S. Food and Drug Administration (FDA) has completed its review of the company’s supplemental New Drug Application seeking full approval of LUMAKRAS® (sotorasib).
